Comparison · NCT02551744-2afcaa9a
Proton Pump Inhibitor Group vs Histamine-2 Receptor Antagonist Group: Number of Participants With Ulcer Recurrence
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Proton Pump Inhibitor Group vs Histamine-2 Receptor Antagonist Group: Number of Participants With Ulcer Recurrence. Trial comparisons, record NCT02551744-2afcaa9a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02551744-2afcaa9a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.02 | 0.00354 | 0.105 | wilson | |
| Risk in group 2 | 0.137 | 0.0681 | 0.257 | wilson | |
| Risk difference, group 1 minus group 2 | -0.117 | -0.238 | -0.00772 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.146 | 0.0186 | 1.14 | log | |
| Odds ratio, group 1 over group 2 | 0.128 | 0.0152 | 1.08 | log | |
| Number needed to treat, for one fewer participant with the outcome on Proton Pump Inhibitor Group than on Histamine-2 Receptor Antagonist Group | 8.53 | 4.2 | 130 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Proton Pump Inhibitor Group | Pantoprazole Tab 40mg qd for 6 monthrs.~proton pump inhibitor group: pantoprazole tab 40 mg qd for 6 months. | 1 | 50 | OG000 |
| Group 2 | Histamine-2 Receptor Antagonist Group | famotidine Tab 40 mg qd for 6 months.~histamine-2 receptor antagonist group: famotidine tab 40 mg qd for 6 months. | 7 | 51 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Ulcer Recurrence
- Description
- Follow-up endoscopy was performed at the end of the 6th month
- Time frame
- six month
- Population
- Intention to treat
Source ClinicalTrials.gov
Trial
- Title
- Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers
- NCT number
- NCT02551744
- Phases
- NA
- Conditions
- Peptic Ulcer
- Interventions
- histamine-2 receptor antagonist group, proton pump inhibitor group
- Lead sponsor
- Kaohsiung Veterans General Hospital.
- Results first posted
- 2019-08-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02551744?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02551744-2afcaa9a